Drug Trial Radar · NCT06295432
A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 1, 2023
Primary completion
Jun 8, 2026
Study completion Jun 8, 2026
Sponsor
- Lead sponsor
- Dizal PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with EGFR mutations who have progressed after standard treatment. The purpose of this study is to assess the safety and efficacy of this combination therapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
DZD9008+AZD4205Drug
Daily dose of DZD9008+AZD4205 until intolerant, disease progression or patient decision. Starting dose of DZD9008 is 200mg once daily and starting dose of AZD4205 is 75mg once daily orally used. If tolerated, subsequent cohorts will evaluate increasing doses of the combination therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: incidence of DLT , ≥grade 3 TEAEs and SAEs; Part B: incidence of ≥grade 3 TEAEs as assessed by CTCAE, incidence of SAEs.Time frame: DLT: 21 days after the first dose; AE that began after the start of trial medication treatment until 28 days after last dose.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Henan Cancer Hospital
Zhengzhou, China
Guangdong Provincial People'S Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.